Intestinal spirochaetosis
Intestinal spirochaetosis is usually a histological finding of Brachyspira organisms attached to the colorectal epithelium. It can represent incidental colonisation or contribute to chronic diarrhoea and abdominal symptoms. The central management question is therefore not simply whether organisms are present, but whether they plausibly explain the patient’s illness. Asymptomatic patients generally do not require treatment; symptomatic patients with no better explanation can reasonably receive a trial of metronidazole.
The best treatment synthesis identified was a 2024 systematic review: 195/233 patients receiving metronidazole-based treatment had a clinical and/or histological response—approximately 84%. However, the evidence was overwhelmingly case reports and small observational series, with short follow-up, rather than randomised trials. This is not an 84% proven durable cure rate.
1. Organisms and microbiology
The principal human-associated species are:
| Organism | Clinically relevant characteristics |
|---|---|
| Brachyspira aalborgi | Fastidious, slowly growing anaerobic spirochaete associated with human colorectal colonisation and intestinal spirochaetosis. |
| Brachyspira pilosicoli | Anaerobic, weakly β-haemolytic spirochaete with a broader animal host range; also associated with rare human bloodstream infections, particularly in critically ill or immunocompromised patients. |
Both organisms are difficult to recover with ordinary laboratory workflows. Older culture studies describe growth taking approximately six days for B. pilosicoli and up to two weeks for B. aalborgi. Consequently, histology and specialist molecular methods are more useful than routine stool culture for establishing the diagnosis.
These are non-treponemal spirochaetes: intestinal spirochaetosis is not synonymous with syphilis. Importantly, Treponema pallidum immunohistochemistry can cross-react with intestinal spirochaetes and is used to highlight them in tissue; a positive tissue stain in this context does not by itself establish syphilis.
2. Epidemiology and transmission
Intestinal spirochaetosis occurs in immunocompetent and immunocompromised people. Higher detection rates have been reported in men who have sex with men, people living with HIV, and populations with greater exposure to faecal contamination. Faecal–oral transmission is considered likely; sexual practices involving faecal–oral exposure may contribute. Nevertheless, an individual diagnosis does not establish the route of acquisition or indicate that the patient has HIV.
Prevalence estimates require caution: studies differ in population, geography and whether they detect organisms in stool or demonstrate epithelial attachment in biopsies. Stool carriage and histologically defined intestinal spirochaetosis are not interchangeable.
A Spanish retrospective cohort of 165 patients supports the association with MSM and sexual exposure, but its selected clinical population should not be treated as representative of the general population.
3. Clinical presentation: colonisation versus disease
Common presentations
Many cases are incidental findings in biopsies taken during investigation or screening. When symptomatic, reported features include:
- Chronic or intermittent watery diarrhoea.
- Abdominal pain or cramps.
- Bloating and IBS-like symptoms.
- Less commonly, rectal bleeding, weight loss, nausea or altered bowel habit.
- In children, diarrhoea with poor weight gain or failure to thrive.
Rare invasive disease and B. pilosicoli bacteraemia have been described, but they are a different clinical problem from uncomplicated incidental mucosal colonisation.
How convincing is the evidence of pathogenicity?
There is evidence of an association with symptoms, but causality remains incompletely resolved:
- A systematic review and meta-analysis found associations with diarrhoea and IBS; the pooled association with Rome III-defined IBS was OR 3.84, 95% CI 1.44–10.20. This establishes an association, not that Brachyspira causes every patient’s IBS.
- Ultrastructural studies describe epithelial attachment, microvillus damage and occasionally invasion, providing biological plausibility for impaired absorption and diarrhoea.
- Symptoms sometimes improve following antibiotic treatment, but some patients remain symptomatic despite histological clearance, while others improve spontaneously.
The practical interpretation is that a positive biopsy supports a possible explanation for otherwise unexplained diarrhoea; it should not stop the search for a more convincing cause.
4. Diagnosis and interpretation of investigations
Histology is the principal diagnostic method
The characteristic finding is a basophilic fringe on the luminal surface of colorectal epithelium on H&E, approximately 3–6 μm thick—the false brush border. Spirochaetes attach approximately perpendicular to the epithelial surface. Warthin–Starry or other silver stains and appropriate immunohistochemistry can help confirm the finding.
Colonoscopy may be macroscopically normal. A normal-looking colon therefore does not exclude intestinal spirochaetosis. Conversely, erythema, polyps or other endoscopic abnormalities do not prove that spirochaetes caused those lesions.
Stool tests, culture and molecular testing
- Routine stool culture is not an adequate exclusion test: the organisms require specialised culture conditions and prolonged incubation.
- PCR and fluorescence in situ hybridisation can identify Brachyspira and differentiate species, including in biopsy material, but access depends on specialist laboratory provision.
- Detection in stool alone is not equivalent to demonstrating the characteristic epithelial colonisation pattern, and it does not establish that the organism is responsible for symptoms.
What else should be investigated?
In a symptomatic patient, the work-up should remain driven by the diarrhoeal syndrome and exposure history. Published clinical reviews emphasise excluding alternative causes, including Giardia, Cryptosporidium, C. difficile, other enteric infections and inflammatory bowel disease; HIV assessment is relevant where status or clinical context warrants it.
Coexisting infection is particularly important: spirochaetosis can occur alongside another enteric pathogen, and treating the histological finding alone may leave the actual cause untreated. A 2025 Lancet Infectious Diseases Grand Round specifically describes chronic intestinal spirochaetosis followed by Giardia infection, illustrating the need to reassess recurrent diarrhoea rather than assume relapse.
5. Treatment
Who should be treated?
| Clinical situation | Reasonable approach |
|---|---|
| Incidental finding, asymptomatic patient | Observation rather than routine antibiotics. |
| Persistent diarrhoea or abdominal symptoms, biopsy-confirmed spirochaetosis, no better explanation | Offer an antibiotic trial, usually metronidazole, with a defined clinical endpoint. |
| Symptoms with another identified enteric pathogen or active gastrointestinal disease | Address the competing diagnosis; do not automatically attribute all symptoms to spirochaetosis. |
| Severe illness, suspected invasive disease or bacteraemia | Specialist infection/microbiology management; do not extrapolate uncomplicated oral treatment regimens to bloodstream infection. |
These approaches reflect observational evidence and clinical reviews rather than a validated treatment algorithm. There is no well-established, universally accepted treatment guideline for intestinal spirochaetosis.
Metronidazole: adult regimens
Published regimens vary, and no comparative trial establishes the optimal dose or duration.
| Published adult regimen | Evidence and interpretation |
|---|---|
| Metronidazole 500 mg orally three times daily | Described as a treatment-of-choice regimen in a clinical case-series review. |
| Metronidazole 400 mg orally three times daily for 10–14 days | Reported in case-based literature; two patients treated for 14 days had symptom resolution. |
| Metronidazole 500 mg orally four times daily for 10 days | Historical successful regimen cited in the major 2010 review; not evidence that this higher daily dose is superior. |
| Seven-day course | Successful treatment has also been reported, although recurrence occurred subsequently in the published case. |
For a UK adult with persistent, plausibly attributable symptoms and uncomplicated biopsy-confirmed disease, a pragmatic literature-supported option is metronidazole 400 mg orally three times daily for 10–14 days, subject to patient-specific prescribing checks and local specialist agreement. This should be described as an evidence-informed treatment trial—not a nationally standardised regimen.
How strong is the treatment evidence?
The 2024 systematic review included:
- 58 publications: 42 case reports, 12 case series, three cross-sectional studies and one prospective cohort.
- 270 treated individuals.
- 225 receiving oral metronidazole monotherapy.
- Overall clinical and/or histological response in 230/270 patients, or 85%.
- Response to metronidazole-based treatment in 195/233 patients, or 84%.
- Median follow-up of only 30 days, IQR 14–90 days.
The main limitations are lack of randomised comparisons, heterogeneous regimens, mixed clinical/histological endpoints, short follow-up and the likelihood that successful cases are preferentially published. Consequently, these data support trying metronidazole in selected symptomatic patients, but do not establish optimal duration, superiority over observation or long-term relapse rates.
Alternatives
Doxycycline is the most useful alternative to discuss when metronidazole is unsuitable: the systematic review included 17 patients receiving doxycycline monotherapy, and the Spanish cohort also reported improvement among patients treated with metronidazole or doxycycline. However, the evidence does not establish a single optimal doxycycline schedule or show equivalence to metronidazole.
Parenteral penicillins and several other antibiotics have been reported, but the numbers are too small to justify considering them interchangeable standard treatments.
Macrolides should not be assumed reliably active merely because occasional successful cases exist: older human B. pilosicoli susceptibility data found erythromycin inactive. Similarly, ciprofloxacin showed unreliable activity. In-vitro activity of ceftriaxone or meropenem is not a reason to use broad-spectrum agents for uncomplicated mucosal disease.
Children
Paediatric case series support metronidazole for symptomatic disease, but treatment evidence is limited and recurrence is reported. One published regimen was 30 mg/kg/day for 10 days; this is a reported regimen, not a universally validated paediatric recommendation. Paediatric prescribing should follow specialist assessment and current weight-based formulary checks.
6. Follow-up, failure and recurrence
A useful approach is to document baseline stool frequency, consistency, pain and weight, then assess clinical response after treatment. Symptoms and organism clearance can diverge, so persistent symptoms should not automatically trigger repeated or prolonged antibiotics.
If symptoms persist or recur:
- Reconsider attribution: was the biopsy finding incidental?
- Reassess for another infection or gastrointestinal diagnosis.
- Review whether there was a genuine initial treatment response.
- Consider persistent colonisation, relapse or re-exposure, recognising that published reports often cannot distinguish these.
- Discuss further investigation or an alternative agent with gastroenterology/microbiology rather than repeatedly treating empirically.
The literature does not establish a standard test-of-cure strategy. Given that histological clearance and symptom resolution do not consistently correlate, routine repeat colonoscopy solely to demonstrate eradication is not supported by the treatment evidence reviewed; repeat endoscopy should be driven by the wider clinical indication.
7. High-yield clinical microbiology points
- A normal colonoscopy does not exclude the diagnosis; the finding is microscopic.
- A positive biopsy does not necessarily identify the cause of diarrhoea.
- Positive T. pallidum immunohistochemistry can highlight Brachyspira and must not automatically be interpreted as syphilis.
- Asymptomatic colonisation usually does not need treatment.
- Metronidazole has the largest published treatment experience, but neither its optimal regimen nor durable efficacy is established.
- Persistent diarrhoea after treatment warrants diagnostic reassessment, not an assumption of antimicrobial resistance.
For clinical decision-making, the 2024 Frontline Gastroenterology systematic review is the most useful treatment evidence identified; the 2023 cohort provides complementary real-world data, while the histopathology reviews help interpret whether the laboratory finding is clinically meaningful.
